Economic aspects of the new Spanish laws on pharmaceutical preparations

  1. Antoñanzas, F. 1
  2. Oliva, J. 2
  3. Pinillos, M. 1
  4. Juàrez, C. 1
  1. 1 Universidad de La Rioja
    info

    Universidad de La Rioja

    Logroño, España

    ROR https://ror.org/0553yr311

  2. 2 Universidad de Castilla-La Mancha
    info

    Universidad de Castilla-La Mancha

    Ciudad Real, España

    ROR https://ror.org/05r78ng12

Zeitschrift:
European Journal of Health Economics

ISSN: 1618-7598

Datum der Publikation: 2007

Ausgabe: 8

Nummer: 3

Seiten: 297-300

Art: Artikel

DOI: 10.1007/S10198-007-0050-9 PMID: 17401592 SCOPUS: 2-s2.0-34547807078 WoS: WOS:000253955000012 GOOGLE SCHOLAR

Andere Publikationen in: European Journal of Health Economics

Zusammenfassung

In this article, we provide readers with a summary of the main economic features of the recently approved Spanish law regarding pharmaceutical preparations entitled the Law of Guarantees and Rational Use of Pharmaceuticals and Health Products (Law 29/2006 of July 26th). We review information on pricing, reference pricing, promotion of generic drugs, public reimbursement, patients' contributions, and penalties. Other aspects of minor economic relevance such as the information on prices shown in the packs and the transparency on the results of clinical trials irrespective of whether these are positive or not, are not addressed in this paper. We conclude with some observations on the new horizons opened up by this new legal framework. We have not included any detailed references to the new law; we merely wish to comment on certain aspects of its application. © 2007 Springer-Verlag.